市场调查报告书
商品编码
1370623
近距离放射治疗设备市场 - 按产品类型、技术、按应用、最终用途 - 全球预测,2023-2032 年Brachytherapy Devices Market - By Product Type, By Technique, By Application, By End-use - Global Forecast, 2023-2032 |
2023 年至2032 年,全球近距离放射治疗设备市场规模将以6.2% 的复合年增长率增长。全球癌症(尤其是前列腺癌和子宫颈癌)发病率的不断上升,正在推动对近距离放射治疗手术的需求,推动产业成长。
此外,技术的进步带来了更精确、更有效率的近距离放射治疗设备,减少了副作用并缩短了治疗持续时间。总部位于瑞典斯德哥尔摩的 Elekta AB 在 2021 年阿拉伯健康大会上推出了其创新的介入放射治疗解决方案。这些解决方案针对癌症护理和脑部疾病进行个性化设计,主要针对肿瘤,同时确保患者安全。
人们越来越认识到微创癌症治疗方案的好处,这将进一步推动业务成长。有利的报销政策和人口老化也将推动市场扩张。
近距离治疗设备市场根据产品类型、技术、应用、最终用途和地区进行分类。
电子近距离放射治疗产品领域 2023 年至 2032 年的复合年增长率将达到 6.5%。电子近距离放射治疗的非侵入性、减少健康组织的辐射暴露以及更短的治疗时间将推动该领域的成长。此外,电子近距离治疗设备的技术进步使其越来越受欢迎,成为各种癌症的首选治疗选择。
高剂量率 (HDR) 技术到 2032 年将呈现 5.8% 的复合年增长率,这得益于其精确性、更短的治疗持续时间以及减少健康组织的辐射暴露。这些优势将使 HDR 近距离放射治疗成为未来几年癌症治疗越来越受欢迎的选择。
根据应用情况,受乳癌发病率增加、对微创治疗的需求以及近距离放射治疗提供有针对性和有效放射的能力等因素的推动,预计乳癌细分市场从2023 年到2032 年的复合年增率将达到6%乳癌患者的治疗。
从地区来看,受癌症患病率上升、有利的报销政策以及该地区先进医疗技术的日益采用等因素的推动,到2032 年,欧洲近距离治疗设备行业将以6.3% 的复合年增长率增长。人们日益关注尽量减少放射治疗的副作用,这将进一步促进该地区产业的成长。
Global brachytherapy devices market size will grow at a 6.2% CAGR from 2023 to 2032. The increasing incidence of cancer worldwide, especially prostate and cervical cancers, is boosting demand for brachytherapy procedures, driving industry growth.
Additionally, advancements in technology are leading to more precise and efficient brachytherapy devices, reducing side effects and treatment durations. Elekta AB, based in Stockholm, Sweden, unveiled its inventive interventional radiotherapy solutions at Arab Health 2021. These solutions, personalized for cancer care and brain disorders, were designed primarily to target tumors while ensuring patient safety.
The growing awareness about the benefits of minimally invasive cancer treatment options will further drive business growth. Favorable reimbursement policies and a rising aging population will also fuel market expansion.
The brachytherapy devices market is categorized based on product type, technique, application, end-use, and region.
The electronic brachytherapy product segment will reflect a 6.5% CAGR over 2023-2032. The non-invasive nature of electronic brachytherapy, its reduced radiation exposure to healthy tissues, and shorter treatment times will drive growth in the segment. Moreover, technological advancements in electronic brachytherapy devices contribute to its rising popularity as a preferred treatment option for various cancers.
The high dose rate (HDR) technique will exhibit a 5.8% CAGR through 2032, driven by its precision, shorter treatment duration, and reduced radiation exposure to healthy tissues. These advantages will make HDR brachytherapy an increasingly preferred choice for cancer treatment in the coming years.
Based on application, the breast cancer segment is anticipated to depict a 6% CAGR from 2023 to 2032, driven by factors such as the increasing incidence of breast cancer, demand for minimally invasive treatments, and the ability of brachytherapy to provide targeted and effective radiation therapy for breast cancer patients.
Regionally, the Europe brachytherapy devices industry will grow at a 6.3% CAGR through 2032, driven by factors such as the rising prevalence of cancer, favorable reimbursement policies, and increasing adoption of advanced medical technologies in the region. The rising focus on minimizing the side effects of radiation therapy will further augment growth in the regional industry.